Anti-MUC1 Aptamer Synthesis and Modification Service

CD Bioparticles offers MUC-1 aptamer synthesis and modification services. We have many years of experience in custom aptamer design and modification and can provide aptamer customisation services for high affinity target proteins suitable for your application. By further modifying the synthesised aptamer, we can provide a reference for better design of targeted drug delivery solutions. Our service provides the basis for exploring whether MUC1 aptamers can be used directly for the selective delivery of cytotoxic agents to cancer cells.

Introduction to the Anti-MUC-1 Aptamer

MUC1 is a well-characterized large transmembrane glycoprotein that can be used as a target for cancer therapy. Its expression is upregulated at least 10-fold in most malignant adenocarcinomas, including breast, lung, and colon cancer, making it an attractive tumor marker for targeted therapy. A typical targeted delivery system typically consists of an anti-cancer drug and a targeting ligand that specifically binds to a tumor marker that is expressed at high levels in cancer cells. The aptamer has been identified as a bioreceptor for the breast cancer biomarker Mucin 1 (MUC1) protein.

Fig. 1 Structure of the MUC1 aptamer. (Yu C, et al., 2011)

Our Anti-MUC1 Aptamer Services

CD Bioparticles specializes in the synthesis and modification of anti-MUC1 aptamer for development. We have chosen MUC1 as the target protein for aptamer targeting. This is because previous studies have shown that aptamers of the MUC1 protein can be used to track cancer cells in the emerging field of targeted delivery. We can also tailor our service to your needs for other types of aptamers. Our service process focuses on but is not limited to the following:

• Anti-MUC1 Aptamer Design

We will work with you to design an aptamer specifically for the MUC1 receptor or any other target protein of interest.

• Anti-MUC1 Aptamer Synthesis

We offer custom anti-MUC1 aptamer synthesis services using a range of technologies including advanced SELEX using modified bases, conventional SELEX using unmodified bases, and mature SELEX.

• Anti-MUC1 Aptamer Modification

We can further modify anti-MUC1 aptamer to improve their binding affinity, stability, and specificity to target proteins. This includes end group (5' and/or 3') modifications with/without linkers (dT, dA, HEG, PEG, etc) and internal modifications, conjugation, etc.

• Anti-MUC1 Aptamer Characterisation

A range of assays can be used to characterize the binding properties of anti-MUC1 aptamer, including surface plasmon resonance (SPR), fluorescence polarisation (FP), and gel shift assays.

• Anti-MUC1 Aptamer Specificity and Affinity Analysis

Flow cytometry and microscopy are used to assess the specificity and affinity of the target.

• Anti-MUC1 Aptamer Targeted Drug Delivery

In vitro and in vivo assays are used to demonstrate the ability of our aptamers to direct tissue-specific drug uptake.

• Anti-MUC1 Aptamer Optimisation

We offer optimization services to improve the properties of aptamers for your specific application. This includes optimization of the aptamer sequence, modification of the aptamer structure, and optimization of the attachment chemistry.

Our Anti-MUC1 Strengths

• Aptamers bind to the target with high affinity and specificity.
• Small size, rapid tissue penetration, easy synthesis, and chemical modification.
• Low toxicity and immunogenicity, stability and a long shelf life.
• A suitable alternative to monoclonal antibodies, peptides, and protein ligands.

Contact us

CD Bioparticles offers anti-MUC1 aptamer synthesis and modification services. Our team can synthesize and modify a wide range of aptamers capable of binding to cell surface receptors. If you are interested in our services, please do not hesitate to contact us.

Quotations and Ordering

References

1. Taylor-Papadimitriou, J.; et al. MUC1 and cancer. Molecular Basis of Disease, 1999, 1455(2-3): 301-313.
2. Maleki, F.; et al. MUC1-Targeted Radiopharmaceuticals in Cancer Imaging and Therapy. Mol Pharm. 2021; 18 (5): 1842-1861.
3. Yu, C.; et al. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One. 2011; 6 (9): e24077.